Prof Michael Dickinson
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
333 Scholarly works
4 Projects
HIGHLIGHTS
2026
Journal article
Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.
DOI: 10.1111/bjh.707772026
Journal article
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.
DOI: 10.1182/bloodadvances.20260216182026
Journal article
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
DOI: 10.1182/bloodadvances.20260200122022
Research grants (other domestic)
Adjuvant Immunotherapy to Improve the Efficacy, Durability, and Cost Effectiveness of CAR T-Cell Therapy for Aggressive Lymphoma
2022
Research grants (other domestic)
Novel Strategies to Predict and Monitor Response to CAR T-Cell Therapy in DLBCL
2019
Journal article
Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma
DOI: 10.1111/bjh.160692017
Research Grant
Targeting Epigenetic Enzymes in Core Binding Factor Aml
RECENT SCHOLARLY WORKS
2026
Journal article
Exploration of experience and sustained engagement with a web-based cognitive rehabilitation intervention amongst patients with aggressive lymphoma: a qualitative sub-study
DOI: 10.1007/s00520-026-10928-z2026
Journal article
Glofitamab monotherapy in patients with Richter transformation: safety and efficacy from a phase 1 study
DOI: 10.1182/bloodadvances.20250181592026
Journal article
Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton's tyrosine kinase inhibitor (BTKi) exposure: Updated data after a 3.5-year follow-up.
DOI: 10.1200/jco.2026.44.16_suppl.70062026
Journal article
Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era
DOI: 10.1111/bjh.704512026
Journal article
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
DOI: 10.1016/S0140-6736(26)00362-42026
Journal article
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
DOI: 10.1182/blood.20250323072026
Journal article
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
DOI: 10.1182/bloodadvances.2026020123
RECENT PROJECTS
2014
Research Grant
Awakening Dormant Genes to Help the Immune System Fight Blood Cancers